GleamWall
中文EN

HALO HALOZYME THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1159036 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY45.0%
TTM net income YoY-18.5%
TTM EPS YoY-15.6%
Revenue 3-yr CAGR32.2%
Net income 3-yr CAGR24.1%

Margins

Gross margin82.3%
Operating margin37.4%
Net margin26.9%
FCF margin49.1%
EBITDA margin38.3%

Returns

ROE216.4%
ROA17.0%
ROIC (approx.)26.6%
Asset turnover0.63x

Leverage & solvency

Liabilities / assets101.6%
Debt / equity—
Current ratio3.88x
Interest coverage30.58x

Cash quality & payout

Operating cash flow / net income1.85x
Accruals ratio-14.5%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.40B$1.02B
Cost of revenue$228.77M$159.42M
Gross profit$1.17B$855.91M
R&D expense$81.49M$79.05M
SG&A expense$207.09M$154.34M
Operating income$469.01M$551.48M
Interest expense$18.13M$18.09M
Pretax income$466.88M$557.13M
Income tax$149.99M$113.04M
Net income$316.89M$444.09M
EBITDA$480.39M$561.74M
EPS (basic)2.643.50
EPS (diluted)2.563.43
Weighted avg. shares (diluted)123.90M129.42M
Balance sheet
Cash & equivalents$133.82M$115.85M
Receivables$426.27M$288.20M
Inventory$176.47M$141.86M
Current assets$825.21M$1.09B
PP&E, net$44.44M$40.86M
Goodwill$580.36M$416.82M
Intangibles$981.47M$401.83M
Total assets$2.53B$2.06B
Current liabilities$177.09M$139.10M
Short-term debt$0$0
Long-term debt$2.14B$1.51B
Total debt$2.14B$1.51B
Total liabilities$2.48B$1.70B
Shareholders' equity$48.81M$363.82M
Net debt$2.01B$1.39B
Shares outstanding117.78M123.14M
Cash flow statement
Operating cash flow$651.56M$479.06M
Capital expenditure$6.97M$10.70M
Free cash flow$644.59M$468.37M
Investing cash flow-$545.81M-$262.72M
Financing cash flow-$85.17M-$218.86M
Depreciation & amortization$11.39M$10.26M
Stock-based compensation$51.56M$43.38M
Share buybacks$342.37M$250.00M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.